Key Highlights

  • C4 Therapeutics is trading 7.83% higher at $3.46, the largest move of the five.
  • Allogene Therapeutics is trading 6.50% higher at $1.31 with 19.73% of its float sold short.
  • Intellia is trading 5.82% higher at $12.97, with an FDA target action date of March 10, 2027 for lonvo-z.
  • Capricor is trading 4.34% higher at $6.36, with an FDA decision on deramiocel due by November 22, 2026.
  • Abeona Therapeutics is trading 2.66% higher at $4.57, with 12.70 days to cover on 17,214,886 shares sold short.

Which Gene-Editing and Cell-Therapy Stocks Are Trading Higher on October 28, 2026?

Five developers of genetic and cellular medicines are trading higher on Wednesday, October 28, 2026. C4 Therapeutics (NASDAQ:CCCC) is trading 7.83% higher at $3.46, Allogene Therapeutics (NASDAQ:ALLO) 6.50% higher at $1.31, Intellia (NASDAQ:NTLA) 5.82% higher at $12.97, Capricor (NASDAQ:CAPR) 4.34% higher at $6.36 and Abeona Therapeutics (NASDAQ:ABEO) 2.66% higher at $4.57.

None of the five has a company release dated today that explains the move. The common thread is positioning, since each single shows a large short position ahead of a regulatory or clinical date. C4 Therapeutics develops protein-degrading medicines rather than gene or cell therapies, so it fits the theme only loosely. Short interest and days to cover come from the October 15 settlement for most names, while Allogene Therapeutics' figure carries no stated date and is described as latest available. Implied prior closes are calculated from the price and the percentage move.

Intellia: Why Is a Heavily Shorted Gene-Editing Stock Trading 5.82% Higher?

Intellia has an implied prior close of about $12.26 (calculated) and a market value near $1.82 billion (calculated). The FDA accepted the lonvo-z application for hereditary angioedema on September 8 with priority review and a March 10, 2027 target date. Short interest for the October 15 settlement was 44,435,219 shares, about 31.7% of shares outstanding (calculated), with 6.45 days to cover.

Cash and marketable securities were $628.4 million at the second-quarter close, and the second-quarter net loss was $106.6 million. Collaboration revenue fell to $7.7 million, mainly on lower revenue from Regeneron (NASDAQ:REGN). Third-quarter results are estimated for around November 9. Research and development expense fell to $82.6 million from $97.0 million, while general and administrative expense rose to $37.8 million on commercial preparation. A United States launch is planned for the first half of 2027 if the product is approved.

Allogene Therapeutics: What Is Behind a 6.50% Gain Without a New Release?

Allogene develops off-the-shelf CAR T therapies, and its stock is among the most heavily traded penny stocks of the session. The implied prior close is near $1.23 (calculated), and the market value is about $453 million on 345.49 million shares. Shares were down about 21% in October as of October 26.

Cash was $423.6 million on June 30, with a runway guided into 2029, and the pivotal ALPHA3 trial in large B-cell lymphoma is enrolling. Latest short interest was 55.61 million shares, 19.73% of float and 9.71 days to cover. A clinical update on ALLO-329 is expected in the fourth quarter. The interim ALPHA3 analysis showed minimal residual disease negativity of 58.3% in the cema-cel arm versus 16.7% in the observation arm, a 41.6-point gap (calculated), though the sample is small.

C4 Therapeutics: Does a 34.7% Short Position Explain the 7.83% Rise?

C4 Therapeutics has an implied prior close near $3.21 (calculated) and a market value of about $426 million (calculated). Short interest for October 15 was 42,722,018 shares, up 2,326,353 from the prior settlement, equal to about 34.7% of shares outstanding. Days to cover were 16.95, and no separate float figure was published.

Its main program is cemsidomide for multiple myeloma, where overall response rates were 40% at 75 micrograms and 53% at 100 micrograms in a small sample. Cash was $300.4 million, which management expects to fund operations through the end of 2028. Partners include Roche and Biogen (NASDAQ:BIIB). The Phase 2 MOMENTUM trial is expected to complete enrollment in the first quarter of 2027, with initial response data in the second half of 2027.

Capricor: Is the 4.34% Rise a Reaction to Short Interest or the FDA Clock?

Capricor has an implied prior close of about $6.10 (calculated). The stock closed at $5.74 on October 26, and shares were down roughly 80% from $28.86 at the start of 2026. Short interest for the October 15 settlement was 19,860,451 shares, or 37.62% of float, with about 6.6 days to cover.

The FDA extended its review of deramiocel for Duchenne muscular dystrophy to November 22, 2026, after an advisory committee voted 9 to 3 against the strength of the heart-benefit evidence in July. The company says its Phase 3 HOPE-3 trial met its primary endpoint. The next quarterly report is estimated for November 9. Capricor reported a second-quarter net loss of $40.7 million on August 13, and its market value was about $333.7 million at the October 26 close.

Abeona Therapeutics: What Could 12.70 Days to Cover Imply for a 2.66% Move?

Abeona Therapeutics has an implied prior close of about $4.45 (calculated) and a market value near $261 million (calculated). Short interest for October 15 was 17,214,886 shares, up 331,997, about 30.1% of the 57.18 million shares outstanding (calculated). Days to cover were 12.70.

Second-quarter net product revenue from its skin-disease therapy Zevaskyn was $11.4 million, up 31% from the first quarter. Cash was $146.8 million on June 30, down about $44.6 million in six months (calculated), and the release gave no cash runway. The company reported third-quarter results on November 12 last year. Medicare's technology add-on payment for Zevaskyn took effect on October 1, 2026, and the treatment network stood at seven qualified centers before another was added.

Gene-Editing and Cell-Therapy Stocks Compared: Which Move Was Largest and Which Short Position Is Heaviest?

C4 Therapeutics outpaced Abeona Therapeutics by 5.17 percentage points (7.83% versus 2.66%), and Allogene Therapeutics beat Capricor by 2.16 percentage points (6.50% versus 4.34%), both calculated. Intellia's $12.97 price is about 9.9 times Allogene Therapeutics' $1.31 (calculated), and its market value is roughly seven times Abeona Therapeutics' (calculated).

On a shares-outstanding basis, C4 Therapeutics at 34.7% sits 3.0 points above Intellia at 31.7% and 4.6 points above Abeona Therapeutics at 30.1% (calculated). Capricor's 37.62% and Allogene Therapeutics' 19.73% are float-based, so they are not ranked against those three. On days to cover, C4 Therapeutics at 16.95 exceeds Intellia's 6.45 by 10.50 days (calculated).

What to Watch Next: October 30 Short-Interest Settlement, November 9 Results and the November 22 Decision

The next short-interest settlement for Intellia, C4 Therapeutics and Abeona Therapeutics is October 30, with publication expected around November 10. Third-quarter reports are estimated for around November 9 at Intellia and Capricor, and the FDA target date for deramiocel is November 22, 2026. Intellia's lonvo-z decision is due March 10, 2027, while Allogene Therapeutics expects its ALLO-329 update in the fourth quarter.